About Illumina
Illumina is a company based in San Diego (United States) founded in 1993 by Mark Chee and Larry Bock. Illumina has raised $28 million across 11 funding rounds from investors including State Farm, United States Department of Agriculture and HHS. The company has 29 employees as of March 31, 2024. Illumina has completed 16 acquisitions, including Advanced Liquid Logic, Affomix and Bluebee. Illumina operates in a competitive market with competitors including DNAnexus, Depixus, Genomics, Seven Bridges Genomics and Hexagon Bio, among others.
- Headquarter San Diego, United States
- Employees 29 as on 31 Mar, 2024
- Founders Mark Chee, Larry Bock
- Stage Public
-
Sectors
HealthcareTechnology
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Illumina India Biotechnology Private Limited
- Date of Incorporation 20 Jun, 2018
- Jurisdiction Sector -45, Haryana, India
-
Annual Revenue
$1.44 M (USD)316.12as on Mar 31, 2023
-
Net Profit
$70.34 K (USD)167as on Mar 31, 2023
-
EBITDA
$328.59 K (USD)835.6as on Mar 31, 2023
-
Total Equity Funding
$28 M (USD)
in 11 rounds
-
Latest Funding Round
Not available
-
Investors
State Farm
& 13 more
-
Employee Count
29
as on Mar 31, 2024
-
Investments & Acquisitions
Advanced Liquid Logic
& 15 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Illumina
Illumina is a publicly listed company on the NASDAQ with ticker symbol ILMN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of Illumina
Unlock access to complete
Unlock access to complete
Software Development Team
249 people
Senior Team
70 people
Leadership Team
67 people
Sales and Marketing
44 people
Staff Team
42 people
Product Management Team
36 people
Finance and Accounting
31 people
Data Analysis and Operations Team
25 people
Unlock access to complete
Funding Insights of Illumina
Illumina has successfully raised a total of $28M across 11 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Illumina
Illumina has secured backing from 14 investors, including institutional and venture fund investors. Prominent investors backing the company include State Farm, United States Department of Agriculture and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on tech sectors
|
Locked | Locked | Locked | |
|
Venture capital firm focused on life science companies
|
Locked | Locked | Locked | |
|
Seed & early stage multiple stage focused corp VC firm funding companies in the US and Canada
|
Locked | Locked | Locked |
Investor details for Illumina
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Illumina
Illumina has strategically engaged in corporate development activities, having acquired 16 companies. Notable acquisitions include Advanced Liquid Logic, Affomix and Bluebee.
Investment portfolio details for Illumina
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Proprietary reagents for single-cell genetic analysis are developed.
|
Locked | Locked | 2018 | Locked | |
|
Circulating tumor DNA is screened for early cancer detection.
|
Locked | Locked | 2016 | Locked | |
|
Next-generation sequencing analysis and genomic data compression are provided.
|
Locked | Locked | 2015 | Locked |
Complete acquisition details for Illumina
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Illumina
Detailed financials for Illumina
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Illumina Comparisons
Peer comparison for Illumina
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Illumina
Illumina operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as DNAnexus, Depixus, Genomics, Seven Bridges Genomics and Hexagon Bio, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Cloud-based genome informatics and data management are provided.
|
|
| Locked | Locked | Locked |
Single-molecule genetic and epigenetic sequencing solutions are provided.
|
|
| Locked | Locked | Locked |
Genomic risk assessment and prevention platform is provided.
|
|
| Locked | Locked | Locked |
Cloud-based platform to analyze, store, and act on genomic data.
|
|
| Locked | Locked | Locked |
Bioinformatics tools are provided for analyzing microbial genomic sequencing data.
|
|
| Locked | Locked | Locked |
DNA sequencing technology is developed to detect genomic mutations.
|
Detailed competitors of Illumina
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Illumina
Complete news archive for Illumina
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Illumina
Illumina was founded in 1993 and raised its 1st funding round 7 years after it was founded.
Illumina is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Illumina is a funded company, having raised a total of $28M across 11 funding rounds to date.
As of Mar 31, 2024, the latest employee count at Illumina is 29.
Annual revenue of Illumina is $1.44M as on Mar 31, 2023.
Developer of technologies for analysis of genetic variation and function. The company provides laboratory instruments, kits, and reagents for research, drug development, and the development of molecular tests. The product categories include gene panel and array finder, microarray kits, clinical research, and IVD products.
Illumina's top competitors include DNAnexus, Depixus and Ingenuity Systems.
Yes, Illumina is publicly traded on NASDAQ under the ticker symbol ILMN.
Illumina has made 16 acquisitions, including Advanced Liquid Logic, Affomix, and Bluebee.
Illumina has 14 investors. Key investors include State Farm, United States Department of Agriculture, HHS, Dow, and Chase.
The ticker symbol of Illumina is ILMN on NASDAQ.